Researchers developed a new algorithm that can use a single OCT scan to predict whether a patient with diabetic macular edema is likely to respond to anti-VEGF treatments. They tested it on pretreatment OCT images (top row) and used post-treatment OCT images (bottom row) to track response to treatment. Case 24 and 36 responded to treatment.
Credit: Sina Farsiu, Duke University
New algorithm poised to help doctors individualize treatment for diabetic macular edema
A new approach that uses artificial intelligence to analyze retinal images could one day help doctors select the best treatment for patients with vision loss from diabetic macular edema. This diabetes complication is a major cause of vision loss among working-age adults.
Anti-vascular endothelial growth factor (VEGF) agents are widely used as the first line of therapy for diabetic macular edema, but they don’t work for everyone. There’s a need to identify who would benefit from the therapy because it requires multiple injections that are costly and burdensome for both patients and physicians.
“We developed an algorithm that can be used to automatically analyze optical coherence tomography (OCT) images of the retina to predict whether a patient is likely to respond to anti-VEGF treatments,” said research team leader Sina Farsiu from Duke University. “This research represents a step toward precision medicine, in which such predictions help clinicians better select first-line therapies for patients based on specific disease conditions.”
In The Optical Society (OSA) journal Biomedical Optics Express, Farsiu and colleagues show that the new algorithm can analyze just one pre-treatment volumetric scan to accurately predict whether a patient is likely to respond to anti-VEGF therapy.
“Our approach could potentially be used in eye clinics to prevent unnecessary and costly trial-and-error treatments and thus alleviate a substantial treatment burden for patients,” Farsiu said. “The algorithm could also be adapted to predict therapy response for many other eye diseases, including neovascular age-related macular degeneration.”
Predicting treatment response
The algorithm developed by the researchers is based on a novel convolutional neural network (CNN) architecture, a type of artificial intelligence that can analyze images by assigning importance to various aspects or objects. They used the algorithm to examine images acquired with OCT, a noninvasive technology that produces high-resolution cross-sectional retinal images and is the standard of care for assessing and treating many eye conditions.
“Unlike previously developed approaches, our algorithm requires OCT images from only a single pretreatment timepoint,” said Reza Rasti, first author of the paper and a postdoctoral scholar in Farsiu’s laboratory. “There’s no need for time-series OCT images, patient records or other metadata to predict therapy response.”
The new algorithm preserves and highlights global structures in the OCT image while enhancing local features from diseased regions to efficiently use retinal thickness information. To help with treatment decision making, the researchers incorporated an additional step that looks for CNN-encoded features that are highly correlated with anti-VEGF response.
Testing the algorithm
The researchers tested their new algorithm with OCT images from 127 patients who had been treated for diabetic macular edema with three consecutive injections of anti-VEGF agents. They applied the algorithm to analyze OCT images taken before the anti-VEGF injections, then compared the algorithm’s predictions to OCT images taken after anti-VEGF therapy to confirm whether the therapy improved the condition.
Based on the results, the researchers calculated that the algorithm would have an 87 percent chance of correctly predicting who would respond to treatment. It exhibited an average precision and specificity of 85 percent and a sensitivity of 80 percent.
Next, the researchers plan to confirm and extend the findings from this pilot study by performing a larger observational trial of patients who have not yet undergone treatment.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Diabetic macular edema
- Ocuphire gets new U.S. patent for its oral drug candidate APX3330 for use in diabetics
Ocuphire Pharma (OCUP) on Wednesday said it had got a new U.S. patent extending the expiry and broadening the coverage of the company's late-stage oral product candidate APX3330.The U.S ...
- EYLEA® (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review
If approved, extended regimen would provide a longer treatment interval and additional dosing flexibility, alongside approved every 4- and 8-week ...
- Diabetic Macular Edema Market In-Depth Analysis, Growth Strategies and Comprehensive Forecast To 2027
The global diabetic macular edema (DME) market is projected to register a sluggish expansion at 1.1% CAGR through 2027, according to a report by Future Market Insights (FMI). The report estimates the ...
- Comprehensive Review of the Effects of Diabetes on Ocular Health
Risks of surgery in diabetic patients include development of clinically significant macular edema and progression of retinopathy. Research suggests that laser-assisted in situkeratomileusis ...
- Vitreomacular Interface Diseases
diabetic macular edema and age-related macular degeneration. The prevalence of many of these serious disorders is rising. Eyes with vitreomacular adhesion-related disorders can experience rapid ...
Go deeper with Google Headlines on:
Diabetic macular edema
Go deeper with Bing News on:
Diabetes related vision loss
- Six ways your eyes can warn you of dangerous health problems
Our eyes are said to be ‘windows to the soul’. But they can also allow you to gain a better understanding of While you might think your issue is just eye- ...
- I’m an expert – here’s the 6 ways your eyes can warn of dangerous health issues
OUR eyes are said to be ‘windows to the soul’. But they can also allow you to gain a better understanding of your overall health. While you might think your issue is just eye-related, ...
- Diabetes type 1: Sufferer details first symptoms - It was ‘typical 4 Ts’
TYPE 1 diabetes is characterised by an inability to produce the hormone insulin. This impairment leaves your blood sugar levels to soar, stirring up various problems. However, this doesn't happen ...
- The relationship between diabetes, and heart disease
THERE is a high rate of diabetes in Jamaica with a prevalence of 11.9 per cent. More females are affected compared to males (14.6 per cent versus nine per cent for males). This translates to ...
- Blurred and spotted vision could be warning sign of type 2 diabetes
When type 2 diabetes is left untreated, the condition can cause damage to your heart, feet, kidneys and eyes - with some extreme cases leading to vision loss. Specsavers in Ashby de la Zouch is ...